| VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 23, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), announced today its lead compound for the treatment of Type 2 diabetes was effective in lowering blood glucose levels in a well-established preclinical diabetic model. Sirona Biochem's compound, SBM-TFC-039, significantly and rapidly reduced the blood glucose level in obese diabetic rats (Zucker). In an acute dosing study, six hours after treatment, the blood gluco...continued SBM:CA SRBCF |
SmallCapUpdates provides the latest news and alerts on stocks for you. If you are looking for the latest on stocks in clean energy, medical innovation, mining, biotech, nanotech, renewable energy, internet technology or in emerging markets.
Pages
▼
No comments:
Post a Comment